Published in Clin Cancer Res on March 15, 2012
Liquid biopsies: genotyping circulating tumor DNA. J Clin Oncol (2014) 4.76
Development of PI3K inhibitors: lessons learned from early clinical trials. Nat Rev Clin Oncol (2013) 3.57
Detection of cancer DNA in plasma of patients with early-stage breast cancer. Clin Cancer Res (2014) 3.50
Liquid biopsy: monitoring cancer-genetics in the blood. Nat Rev Clin Oncol (2013) 3.34
Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA. Clin Cancer Res (2014) 3.28
Combinatorial drug therapy for cancer in the post-genomic era. Nat Biotechnol (2012) 3.10
Semiautomated isolation and molecular characterisation of single or highly purified tumour cells from CellSearch enriched blood samples using dielectrophoretic cell sorting. Br J Cancer (2013) 1.51
BEAMing and Droplet Digital PCR Analysis of Mutant IDH1 mRNA in Glioma Patient Serum and Cerebrospinal Fluid Extracellular Vesicles. Mol Ther Nucleic Acids (2013) 1.40
Circulating tumour cells and cell-free DNA as tools for managing breast cancer. Nat Rev Clin Oncol (2013) 1.33
Integrated digital error suppression for improved detection of circulating tumor DNA. Nat Biotechnol (2016) 1.32
Serial Next-Generation Sequencing of Circulating Cell-Free DNA Evaluating Tumor Clone Response To Molecularly Targeted Drug Administration. Clin Cancer Res (2015) 1.29
ESR1 Mutations in Circulating Plasma Tumor DNA from Metastatic Breast Cancer Patients. Clin Cancer Res (2015) 1.18
Treatment of HER2-positive breast cancer. Breast (2013) 1.09
EGFR-TKI resistance in NSCLC patients: mechanisms and strategies. Am J Cancer Res (2014) 1.08
Longitudinal monitoring of EGFR mutations in plasma predicts outcomes of NSCLC patients treated with EGFR TKIs: Korean Lung Cancer Consortium (KLCC-12-02). Oncotarget (2016) 1.03
Integrating liquid biopsies into the management of cancer. Nat Rev Clin Oncol (2017) 0.94
Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapies. Oncotarget (2015) 0.92
Circulating Cell-Free Tumour DNA in the Management of Cancer. Int J Mol Sci (2015) 0.90
Translating metastasis-related biomarkers to the clinic--progress and pitfalls. Nat Rev Clin Oncol (2013) 0.88
Clinical utility of a blood-based BRAF(V600E) mutation assay in melanoma. Mol Cancer Ther (2014) 0.86
Comparison of cell stabilizing blood collection tubes for circulating plasma tumor DNA. Clin Biochem (2015) 0.85
Pilot studies for personalized cancer medicine: focusing on the patient for treatment selection. Oncologist (2013) 0.85
Cell-free circulating tumor DNA in cancer. Chin J Cancer (2016) 0.85
Testing for oncogenic molecular aberrations in cell-free DNA-based liquid biopsies in the clinic: are we there yet? Expert Rev Mol Diagn (2015) 0.84
Panitumumab in Metastatic Colorectal Cancer: The Importance of Tumour RAS Status. Drugs (2015) 0.83
Clinical significance of monitoring ESR1 mutations in circulating cell-free DNA in estrogen receptor positive breast cancer patients. Oncotarget (2016) 0.83
A PIK3CA mutation detected in plasma from a patient with synchronous primary breast and lung cancers. Hum Pathol (2013) 0.82
AKT1 (E17K) mutation profiling in breast cancer: prevalence, concurrent oncogenic alterations, and blood-based detection. BMC Cancer (2016) 0.80
BEAMing up personalized medicine: mutation detection in blood. Clin Cancer Res (2012) 0.79
Plasma tumor DNA: on your markers, get set, go! Ann Transl Med (2014) 0.78
Breast Cancer Biomarkers: Utility in Clinical Practice. Curr Breast Cancer Rep (2013) 0.78
Circulating biomarkers to monitor cancer progression and treatment. Comput Struct Biotechnol J (2016) 0.78
Liquid biopsy for detection of actionable oncogenic mutations in human cancers and electric field induced release and measurement liquid biopsy (eLB). Analyst (2016) 0.78
Correlation between PIK3CA mutations in cell-free DNA and everolimus efficacy in HR(+), HER2(-) advanced breast cancer: results from BOLERO-2. Br J Cancer (2017) 0.77
Tumor burden monitoring using cell-free tumor DNA could be limited by tumor heterogeneity in advanced breast cancer and should be evaluated together with radiographic imaging. BMC Cancer (2017) 0.77
Multiscale Cues Drive Collective Cell Migration. Sci Rep (2016) 0.77
Phosphoinositide-3-kinase, catalytic, alpha polypeptide RNA interference inhibits growth of colon cancer cell SW948. World J Gastroenterol (2012) 0.77
Current and Emerging Applications of Droplet Digital PCR in Oncology. Mol Diagn Ther (2017) 0.76
The Evolving Role of Circulating Tumor Cells in the Personalized Management of Breast Cancer: from Enumeration to Molecular Characterization. Curr Breast Cancer Rep (2014) 0.76
Detection fidelity of AR mutations in plasma derived cell-free DNA. Oncotarget (2017) 0.76
Individualized Molecular Analyses Guide Efforts (IMAGE): A Prospective Study of Molecular Profiling of Tissue and Blood in Metastatic Triple-Negative Breast Cancer. Clin Cancer Res (2016) 0.76
SNPase-ARMS qPCR: Ultrasensitive Mutation-Based Detection of Cell-Free Tumor DNA in Melanoma Patients. PLoS One (2015) 0.76
Strategies for monitoring and combating resistance to combination kinase inhibitors for cancer therapy. Genome Med (2017) 0.75
Noninvasive Digital Detection of Fetal DNA in Plasma of 4-Week-Pregnant Women following In Vitro Fertilization and Embryo Transfer. PLoS One (2015) 0.75
Enhancing Endocrine Therapy Combination Strategies for the Treatment of Postmenopausal Hormone Receptor-Positive/HER2- Advanced Breast Cancer. Oncologist (2016) 0.75
Detecting Circulating Tumor DNA in Hepatocellular Carcinoma Patients Using Droplet Digital PCR Is Feasible and Reflects Intratumoral Heterogeneity. J Cancer (2016) 0.75
Emerging methods for disease monitoring in malignant gliomas. CNS Oncol (2013) 0.75
Value of circulating cell-free DNA analysis as a diagnostic tool for breast cancer: a meta-analysis. Oncotarget (2017) 0.75
Diagnostic Accuracy of PIK3CA Mutation Detection by Circulating Free DNA in Breast Cancer: A Meta-Analysis of Diagnostic Test Accuracy. PLoS One (2016) 0.75
Pharmacogenomics of Targeted Agents for Personalization of Colorectal Cancer Treatment. Int J Mol Sci (2017) 0.75
Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol (2017) 0.75
Detection of PIK3CA Mutations in Plasma DNA of Colorectal Cancer Patients by an Ultra-Sensitive PNA-Mediated PCR. Mol Diagn Ther (2017) 0.75
Mutation-Enrichment Next-Generation Sequencing for Quantitative Detection of KRAS Mutations in Urine Cell-Free DNA from Patients with Advanced Cancers. Clin Cancer Res (2017) 0.75
Circulating Tumor DNA as Biomarkers for Cancer Detection. Genomics Proteomics Bioinformatics (2017) 0.75
Correlation Between Circulating Tumor DNA Levels and Response to Tyrosine Kinase Inhibitors (TKI) Treatment in Non-Small Cell Lung Cancer. Med Sci Monit (2017) 0.75
Liquid biopsy: unlocking the potentials of cell-free DNA. Virchows Arch (2017) 0.75
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med (2004) 71.08
Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med (2010) 36.57
K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med (2008) 27.35
Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol (2008) 20.89
Tumour evolution inferred by single-cell sequencing. Nature (2011) 19.13
Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature (2010) 17.38
Transforming single DNA molecules into fluorescent magnetic particles for detection and enumeration of genetic variations. Proc Natl Acad Sci U S A (2003) 12.91
Circulating mutant DNA to assess tumor dynamics. Nat Med (2007) 10.33
PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. Cancer Res (2005) 8.98
An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res (2008) 8.12
The PIK3CA gene is mutated with high frequency in human breast cancers. Cancer Biol Ther (2004) 7.82
Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Res (2004) 6.65
Detection and quantification of mutations in the plasma of patients with colorectal tumors. Proc Natl Acad Sci U S A (2005) 5.91
Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer. J Clin Oncol (2007) 5.55
Cellular and genetic diversity in the progression of in situ human breast carcinomas to an invasive phenotype. J Clin Invest (2010) 4.22
PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors. Mol Cancer Ther (2011) 4.22
BEAMing: single-molecule PCR on microparticles in water-in-oil emulsions. Nat Methods (2006) 4.21
PIK3CA mutation associates with improved outcome in breast cancer. Clin Cancer Res (2009) 3.95
Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res (2010) 3.20
Mutation of the PIK3CA oncogene in human cancers. Br J Cancer (2006) 3.04
BEAMing up for detection and quantification of rare sequence variants. Nat Methods (2006) 3.03
PI3K pathway mutations and PTEN levels in primary and metastatic breast cancer. Mol Cancer Ther (2011) 2.50
PIK3CA mutations may be discordant between primary and corresponding metastatic disease in breast cancer. Clin Cancer Res (2010) 2.13
Intratumor genomic heterogeneity in breast cancer with clonal divergence between primary carcinomas and lymph node metastases. Breast Cancer Res Treat (2006) 2.04
Detection of PIK3CA mutations in circulating free DNA in patients with breast cancer. Breast Cancer Res Treat (2010) 1.59
Clinicopathologic analysis of breast cancers with PIK3CA mutations in Japanese women. Clin Cancer Res (2007) 1.49
Multiplexed assays for detection of mutations in PIK3CA. Clin Chem (2008) 1.36
The selective class I PI3K inhibitor CH5132799 targets human cancers harboring oncogenic PIK3CA mutations. Clin Cancer Res (2011) 1.34
A SNaPshot assay for the rapid and simple detection of four common hotspot codon mutations in the PIK3CA gene. BMC Res Notes (2009) 1.29
Acquired KRAS mutations during progression of colorectal cancer metastases: possible implications for therapy and prognosis. Cancer Chemother Pharmacol (2010) 1.14
Current status and future potential of somatic mutation testing from circulating free DNA in patients with solid tumours. Hugo J (2011) 1.13
Phenotype of bone metastases of non-small cell lung cancer: epidermal growth factor receptor expression and K-RAS mutational status. Pathol Oncol Res (2007) 1.04
The consensus coding sequences of human breast and colorectal cancers. Science (2006) 60.02
An integrated genomic analysis of human glioblastoma multiforme. Science (2008) 51.36
Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science (2008) 36.02
affy--analysis of Affymetrix GeneChip data at the probe level. Bioinformatics (2004) 32.08
Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. Nature (2010) 23.55
American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol (2010) 14.41
Molecular definition of breast tumor heterogeneity. Cancer Cell (2007) 12.67
2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol (2006) 11.26
Comparative lesion sequencing provides insights into tumor evolution. Proc Natl Acad Sci U S A (2008) 10.52
Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach? Nat Rev Drug Discov (2009) 10.32
Selective killing of oncogenically transformed cells through a ROS-mediated mechanism by beta-phenylethyl isothiocyanate. Cancer Cell (2006) 10.10
A stem cell-like chromatin pattern may predispose tumor suppressor genes to DNA hypermethylation and heritable silencing. Nat Genet (2007) 9.47
DNMT1 and DNMT3b cooperate to silence genes in human cancer cells. Nature (2002) 9.40
American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. J Clin Oncol (2005) 8.56
Heritable gene targeting in zebrafish using customized TALENs. Nat Biotechnol (2011) 8.34
microRNAs exhibit high frequency genomic alterations in human cancer. Proc Natl Acad Sci U S A (2006) 8.24
The PIK3CA gene is mutated with high frequency in human breast cancers. Cancer Biol Ther (2004) 7.82
Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. N Engl J Med (2014) 6.76
American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol (2004) 6.59
Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med (2008) 6.54
American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Clin Oncol (2010) 6.39
Development of personalized tumor biomarkers using massively parallel sequencing. Sci Transl Med (2010) 6.08
The circadian gene Period2 plays an important role in tumor suppression and DNA damage response in vivo. Cell (2002) 6.05
CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst (2005) 5.92
Adjuvant chemotherapy in older women with early-stage breast cancer. N Engl J Med (2009) 5.68
Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. J Clin Oncol (2014) 5.61
Notch mediates TGF alpha-induced changes in epithelial differentiation during pancreatic tumorigenesis. Cancer Cell (2003) 5.36
Glucose deprivation contributes to the development of KRAS pathway mutations in tumor cells. Science (2009) 5.31
High-resolution analysis of DNA copy number using oligonucleotide microarrays. Genome Res (2004) 5.24
ROS stress in cancer cells and therapeutic implications. Drug Resist Updat (2004) 5.20
Targeting autophagy augments the anticancer activity of the histone deacetylase inhibitor SAHA to overcome Bcr-Abl-mediated drug resistance. Blood (2007) 4.91
Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment. Clin Pharmacol Ther (2006) 4.81
Genomic and epigenetic alterations deregulate microRNA expression in human epithelial ovarian cancer. Proc Natl Acad Sci U S A (2008) 4.79
American Society of Clinical Oncology 2006 update of the breast cancer follow-up and management guidelines in the adjuvant setting. J Clin Oncol (2006) 4.61
Subtype and pathway specific responses to anticancer compounds in breast cancer. Proc Natl Acad Sci U S A (2011) 4.55
CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients. J Natl Cancer Inst (2012) 4.54
Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus: a systematic review and meta-analysis. JAMA (2008) 4.48
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). Arch Pathol Lab Med (2010) 4.38
Redox regulation of cell survival. Antioxid Redox Signal (2008) 4.33
Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol (2008) 4.29
miR-210 links hypoxia with cell cycle regulation and is deleted in human epithelial ovarian cancer. Cancer Biol Ther (2007) 3.93
Transient low doses of DNA-demethylating agents exert durable antitumor effects on hematological and epithelial tumor cells. Cancer Cell (2012) 3.82
Inhibition of glycolysis in cancer cells: a novel strategy to overcome drug resistance associated with mitochondrial respiratory defect and hypoxia. Cancer Res (2005) 3.79
Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia. Blood (2004) 3.76
The International Society of Urological Pathology (ISUP) Vancouver Classification of Renal Neoplasia. Am J Surg Pathol (2013) 3.68
Heterogeneity of breast cancer metastases: comparison of therapeutic target expression and promoter methylation between primary tumors and their multifocal metastases. Clin Cancer Res (2008) 3.67
Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update. J Clin Oncol (2006) 3.52
Comparing the DNA hypermethylome with gene mutations in human colorectal cancer. PLoS Genet (2007) 3.39
Systematic review: gene expression profiling assays in early-stage breast cancer. Ann Intern Med (2008) 3.32
Molecular target class is predictive of in vitro response profile. Cancer Res (2010) 3.27
Exemestane versus anastrozole in postmenopausal women with early breast cancer: NCIC CTG MA.27--a randomized controlled phase III trial. J Clin Oncol (2013) 3.24
STAC: A method for testing the significance of DNA copy number aberrations across multiple array-CGH experiments. Genome Res (2006) 3.21
Breast cancer. Clinical practice guidelines in oncology. J Natl Compr Canc Netw (2009) 3.17
Comparison of Sanger sequencing, pyrosequencing, and melting curve analysis for the detection of KRAS mutations: diagnostic and clinical implications. J Mol Diagn (2010) 3.12
Novel mechanism of lapatinib resistance in HER2-positive breast tumor cells: activation of AXL. Cancer Res (2009) 3.10
Serial assessment of human tumor burdens in mice by the analysis of circulating DNA. Cancer Res (2007) 3.05
BEAMing up for detection and quantification of rare sequence variants. Nat Methods (2006) 3.03
Genome-wide associations and functional genomic studies of musculoskeletal adverse events in women receiving aromatase inhibitors. J Clin Oncol (2010) 3.02
Cell type-specific DNA methylation patterns in the human breast. Proc Natl Acad Sci U S A (2008) 2.99
Efficient and specific modifications of the Drosophila genome by means of an easy TALEN strategy. J Genet Genomics (2012) 2.98
Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: a mutational analysis with immunohistochemical correlation. Am J Surg Pathol (2005) 2.83
Global 5-hydroxymethylcytosine content is significantly reduced in tissue stem/progenitor cell compartments and in human cancers. Oncotarget (2011) 2.80
Conventional adjuvant chemotherapy with or without high-dose chemotherapy and autologous stem-cell transplantation in high-risk breast cancer. N Engl J Med (2003) 2.79
Sequence mutations and amplification of PIK3CA and AKT2 genes in purified ovarian serous neoplasms. Cancer Biol Ther (2006) 2.76
Mitochondrial defects in cancer. Mol Cancer (2002) 2.75
Chromosomal deletions and inversions mediated by TALENs and CRISPR/Cas in zebrafish. Nucleic Acids Res (2013) 2.73
High resolution genomic analysis of sporadic breast cancer using array-based comparative genomic hybridization. Breast Cancer Res (2005) 2.72
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. Arch Pathol Lab Med (2010) 2.72
Loss of the tight junction protein claudin-7 correlates with histological grade in both ductal carcinoma in situ and invasive ductal carcinoma of the breast. Oncogene (2003) 2.71
Transitioning to breast cancer survivorship: perspectives of patients, cancer specialists, and primary care providers. J Gen Intern Med (2009) 2.70
Mitochondrial respiration defects in cancer cells cause activation of Akt survival pathway through a redox-mediated mechanism. J Cell Biol (2006) 2.68
Consensus report of the national cancer institute clinical trials planning meeting on pancreas cancer treatment. J Clin Oncol (2009) 2.66
Silencing of Irf7 pathways in breast cancer cells promotes bone metastasis through immune escape. Nat Med (2012) 2.66
HOXB7, a homeodomain protein, is overexpressed in breast cancer and confers epithelial-mesenchymal transition. Cancer Res (2006) 2.66
TALEN-mediated precise genome modification by homologous recombination in zebrafish. Nat Methods (2013) 2.64
Multicomponent analysis of the pancreatic adenocarcinoma progression model using a pancreatic intraepithelial neoplasia tissue microarray. Mod Pathol (2003) 2.63
Breast cancer follow-up and management after primary treatment: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol (2012) 2.62
American society of clinical oncology/college of american pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Oncol Pract (2010) 2.59
Stromal control of cystine metabolism promotes cancer cell survival in chronic lymphocytic leukaemia. Nat Cell Biol (2012) 2.59
Molecular markers in ductal carcinoma in situ of the breast. Mol Cancer Res (2003) 2.55
Diabetes mellitus and breast cancer outcomes: a systematic review and meta-analysis. J Clin Oncol (2010) 2.46
TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer. J Clin Oncol (2012) 2.45
FLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AML. Blood (2009) 2.44
Modeling precision treatment of breast cancer. Genome Biol (2013) 2.42
Prevalence of the alternative lengthening of telomeres telomere maintenance mechanism in human cancer subtypes. Am J Pathol (2011) 2.41
Sequence survey of receptor tyrosine kinases reveals mutations in glioblastomas. Proc Natl Acad Sci U S A (2005) 2.38
Comparing care for breast cancer survivors to non-cancer controls: a five-year longitudinal study. J Gen Intern Med (2009) 2.36
MicroRNA microarray identifies Let-7i as a novel biomarker and therapeutic target in human epithelial ovarian cancer. Cancer Res (2008) 2.35
PTEN protein loss by immunostaining: analytic validation and prognostic indicator for a high risk surgical cohort of prostate cancer patients. Clin Cancer Res (2011) 2.35
Sensitive digital quantification of DNA methylation in clinical samples. Nat Biotechnol (2009) 2.34
Quantitative multiplex methylation-specific PCR assay for the detection of promoter hypermethylation in multiple genes in breast cancer. Cancer Res (2004) 2.29
Newer antidepressants and gabapentin for hot flashes: a discussion of trial duration. Menopause (2009) 2.27
Prevention, screening, and surveillance care for breast cancer survivors compared with controls: changes from 1998 to 2002. J Clin Oncol (2009) 2.26
Novel role of p53 in maintaining mitochondrial genetic stability through interaction with DNA Pol gamma. EMBO J (2005) 2.25
Bortezomib inhibits PKR-like endoplasmic reticulum (ER) kinase and induces apoptosis via ER stress in human pancreatic cancer cells. Cancer Res (2005) 2.22
Inhibition of mitochondrial respiration: a novel strategy to enhance drug-induced apoptosis in human leukemia cells by a reactive oxygen species-mediated mechanism. J Biol Chem (2003) 2.19
MUC4 expression increases progressively in pancreatic intraepithelial neoplasia. Am J Clin Pathol (2002) 2.18
DNA methylation of RASSF1A, HIN-1, RAR-beta, Cyclin D2 and Twist in in situ and invasive lobular breast carcinoma. Int J Cancer (2003) 2.18